Potent and selective TRPA1 antagonist (IC50 = 0.02 μM for human TRPA1). Exhibits no siginificant activity against human TRPV1 or TRPV4, and rat TRPV1, TRPV3 or TRPM8. Exhibits efficacy in a rat pain model. Orally bioavailable.
We use some essential cookies to make this website work. These cookies aren't used to track you. We'd
like
to set additional cookies to understand how you use our website. This information is used to improve
our
services.